Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART19 in Relapsed/Refractory B-Cell Malignancies
NCT04384393Phase 1Unknown
- Sponsor
- Fundamenta Therapeutics Inc.
- Start
- May 2020
- Primary completion
- Nov 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of thiscart19a in B-cell malignancy, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and 1 more, sponsored by Fundamenta Therapeutics Inc. Primary endpoints: Incidence of Dose Limiting Toxicities at Day 28, Complete Remission at Day 28 and 1 more. Status: unknown.
02
Drugs
thiscart19a
03
Conditions
B-cell malignancyacute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)lymphoma
Beyond the preview
Go deeper on NCT04384393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04384393.